citalopram has been researched along with 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouchez, G; Brocco, M; Dekeyne, A; Di Cara, B; Gannon, RL; Gobert, A; Lejeune, F; Millan, MJ | 1 |
1 other study(ies) available for citalopram and 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one
| Article | Year |
|---|---|
Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Brain; Citalopram; Cricetinae; Dopamine; Drug Synergism; Fluoxetine; Gerbillinae; Isoindoles; Male; Mesocricetus; Mice; Neurokinin-1 Receptor Antagonists; Neurons; Norepinephrine; Piperidines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Tetrazoles | 2009 |